Business Context and Reporting Period
OraSure Technologies, Inc. filed this Form 8-K on January 18, 2002, to announce preliminary financial results for the quarter and full year ended December 31, 2001. The company operates in the oral fluid testing market, focusing on drugs of abuse and HIV-1 detection.
Key Financial Metrics
| Metric | Q4 2001 (Preliminary) | Full Year 2001 (Preliminary) | Q4 2000 | Full Year 2000 |
|---|---|---|---|---|
| Revenue | $8.1 million | $32.6 million | Not explicitly stated | Not explicitly stated |
| Net Loss | $1.6 - $1.8 million | $3.0 - $3.2 million | $3.7 million | $12.7 million |
| Revenue Growth (YoY) | 9% | 20% | N/A | N/A |
Note: 2000 revenue figures were adjusted to exclude discontinued products for comparison. The 2000 net loss included merger-related charges of $1.7 million for the quarter and $7.6 million for the full year.
The filing does not provide specific values for cash flow, debt, liquidity, or gross margin percentages, though management noted the company maintains "high gross margins."
Material Changes and Drivers
- Revenue Decline vs. Expectations: Preliminary revenues were lower than anticipated due to unexpected inventory reductions by two major insurance clients following a merger, lower international sales, and soft market conditions.
- Profitability Improvement: Despite lower revenues, the net loss for 2001 is significantly reduced compared to 2000, largely due to the absence of the $7.6 million in merger-related charges recorded in the prior year.
- Product Performance:
- OraSure HIV-1: Q4 sales increased by over $600,000 (approx. 65% YoY); Full year sales increased by over $1.6 million (approx. 50% YoY).
- Intercept Drugs of Abuse: Q4 sales increased by over $800,000 (approx. 980% YoY); Full year sales increased by over $3.1 million (approx. 1,000% YoY).
- Expense Increases: Expenses rose due to the UPlink Drugs of Abuse FDA submission and corporate partnering activities.
Guidance, Outlook, and Risks
2002 Outlook: Subject to regulatory approvals and market acceptance of new products (OraQuick rapid HIV test and UPlink Drugs of Abuse test), the company reaffirmed its expectation of profitability and a revenue growth target of 30% over 2001 levels.
Upcoming Events: Actual results for Q4 and full year 2001 are expected to be reported on February 15, 2002. A conference call was scheduled for January 22, 2002.
Risks and Contingencies: The filing lists numerous factors that could cause actual results to differ, including:
- Regulatory approval timing for new products.
- Market acceptance of oral fluid testing and up-converting phosphor technology.
- Reliance on strategic partners and potential changes in those relationships.
- Patent protection uncertainties and potential infringement claims.
- International manufacturing and marketing obstacles.
- Product liability litigation and changes in laws/regulations.
Investor Verification Checklist
- Verify the final audited revenue and net loss figures when reported on February 15, 2002, as current numbers are preliminary.
- Confirm the status of regulatory approvals for the OraQuick rapid HIV test and UPlink Drugs of Abuse test, which are critical to the 2002 profitability guidance.
- Assess the impact of the merger between the company's two largest insurance clients on future order volumes.
- Review the upcoming 10-K and 10-Q filings for detailed cash flow, debt, and liquidity data not provided in this 8-K.
- Monitor the progress of the UPlink FDA submission and associated expense impacts.